1324. In Vitro Activity of Ceftazidime-Avibactam (CAZ-AVI) against Urinary Tract Infection (UTI) and Intra-Abdominal Infection (IAI) Pathogens from Latin America: Results of the INFORM Surveillance Initiative
Session: Poster Abstract Session: Clinical Infectious Diseases: Urinary Tract Infections
Friday, October 28, 2016
Room: Poster Hall
Posters
  • AZ_ P3_ CAZ AVI LATAM_IDSA 2016_v01_final.pdf (428.6 kB)
  • Background: Increasing resistance in Gram-negative pathogens has been reported worldwide, seriously limiting treatment options in some regions. Avibactam is a novel non-β-lactam β-lactamase inhibitor that restores the in vitro activity of ceftazidime against Enterobacteriaceae that produce class A (including KPC), class C, and some class D β-lactamases. In this study we evaluated the in vitro activity of ceftazidime-avibactam (CAZ-AVI) against Enterobacteriaceae collected from UTI and IAI sources across Latin America. 

    Methods: Isolates for this analysis were collected from 2012 – 2014 from six countries in Latin America.  All isolates came from either a UTI or IAI source and were collected centrally for confirmatory identification and antimicrobial susceptibility testing.  MICs were determined by broth microdilution according to CLSI guidelines for testing and interpretations.  The percent susceptible (%S) was assessed using the FDA breakpoint of ≤8 mg/ml for CAZ-AVI with AVI tested at a constant concentration of 4 mg/ml.

    Results: The CAZ-AVI activities against each organism group within each of the six countries is shown below.   

    Organism

    Argentina

    Brazil

    Chile

    Colombia

    Mexico

    Venezuela

     

    n

    %S/MIC90

    n

    %S/MIC90

    n

    %S/MIC90

    n

    %S/MIC90

    n

    %S/MIC90

    n

    %S/MIC90

    All Enterobacteriaceae

    499

    99.2/0.5

    513

    99.8/1

    590

    100/1

    377

    100/0.5

    494

    99.8/0.25

    430

    100/0.25

    Escherichia coli

    232

    100/0.25

    218

    100/0.25

    267

    100/0.25

    151

    100/0.25

    202

    100/0.25

    177

    100/0.25

    Klebsiella spp.

    123

    99.2/1

    156

    99.4/2

    177

    100/2

    111

    100/0.5

    148

    100/0.25

    129

    100/0.5

    Conclusion: Based on MIC90s and % susceptibility CAZ-AVI demonstrated potent in vitro activity against all Enterobacteriaceae encountered from UTI and IAI specimens obtained from several countries in Latin America over the three years studied. This activity included the most prominent species E. coli and Klebsiella spp. Currently these data demonstrate that CAZ-AVI has potent activity against all targeted species. However, this level of potency could change if these organisms acquire other potent b-lactamases (e.g. MBLs).

     

     

    Meredith Hackel, PhD, MPH1, Douglas Biedenbach, MS1, Gregory G. Stone, PhD2, Boudewijn Dejonge, PhD3 and Dan Sahm, PhD1, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)AstraZeneca, Waltham, MA, (3)AstraZeneca Pharmaceuticals, Waltham, MA

    Disclosures:

    M. Hackel, IHMA, Inc.: Independent Contractor , Research support

    D. Biedenbach, IHMA, Inc.: Independent Contractor , Research support

    G. G. Stone, AstraZeneca: Employee and Shareholder , Salary

    B. Dejonge, AstraZeneca Pharmaceuticals: Employee and Shareholder , Salary

    D. Sahm, IHMA, Inc.: Independent Contractor , Research support

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.